ATE412175T1 - Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz - Google Patents

Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz

Info

Publication number
ATE412175T1
ATE412175T1 AT05011041T AT05011041T ATE412175T1 AT E412175 T1 ATE412175 T1 AT E412175T1 AT 05011041 T AT05011041 T AT 05011041T AT 05011041 T AT05011041 T AT 05011041T AT E412175 T1 ATE412175 T1 AT E412175T1
Authority
AT
Austria
Prior art keywords
immunological tolerance
induce immunological
cryptic peptides
cryptic
peptides
Prior art date
Application number
AT05011041T
Other languages
English (en)
Inventor
Anthony Barrington Kay
Mark Larche
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605904.3A external-priority patent/GB9605904D0/en
Priority claimed from GBGB9608430.6A external-priority patent/GB9608430D0/en
Application filed by Circassia Ltd filed Critical Circassia Ltd
Application granted granted Critical
Publication of ATE412175T1 publication Critical patent/ATE412175T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Insects & Arthropods (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
AT05011041T 1996-03-21 1997-03-20 Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz ATE412175T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9605904.3A GB9605904D0 (en) 1996-03-21 1996-03-21 Peptides
GBGB9608430.6A GB9608430D0 (en) 1996-04-24 1996-04-24 Peptides

Publications (1)

Publication Number Publication Date
ATE412175T1 true ATE412175T1 (de) 2008-11-15

Family

ID=26308965

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05011041T ATE412175T1 (de) 1996-03-21 1997-03-20 Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz
AT97908389T ATE296444T1 (de) 1996-03-21 1997-03-20 Kryptische peptide und verfahren zu ihrer identifizierung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97908389T ATE296444T1 (de) 1996-03-21 1997-03-20 Kryptische peptide und verfahren zu ihrer identifizierung

Country Status (11)

Country Link
US (1) US6737406B1 (de)
EP (2) EP0888541B1 (de)
JP (1) JP4340329B2 (de)
AT (2) ATE412175T1 (de)
AU (1) AU730198C (de)
CA (1) CA2247009C (de)
DE (2) DE69739062D1 (de)
DK (1) DK1612555T3 (de)
ES (1) ES2314515T3 (de)
GB (3) GB2349463B (de)
WO (1) WO1997035193A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812087B1 (fr) 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
WO2002066979A1 (en) * 2001-02-22 2002-08-29 Takara Bio Inc. Method of detecting antigen causative of bronchial asthma
AU2003273679A1 (en) * 2002-06-11 2003-12-22 Merck Patent Gmbh Method for mapping and eliminating t-cell epitopes
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
WO2025194374A1 (zh) * 2024-03-20 2025-09-25 深圳赫兹生命科学技术有限公司 猫过敏原多肽片段及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
JP2633881B2 (ja) 1986-06-30 1997-07-23 マサチューセッツ インスティテュート オブ テクノロジー 免疫調節組成物及びそれらの使用
US6180368B1 (en) 1988-03-23 2001-01-30 University Of Melbourne Ryegrass pollen allergen
EP0463059B1 (de) 1989-03-17 1998-12-30 Immulogic Pharmaceutical Corporation Allergene proteine aus ambrosia und verwendung davon
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5328991A (en) 1989-11-03 1994-07-12 Immulogic Pharmaceutical Corp. Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
EP0500785B1 (de) * 1989-11-03 2002-04-17 Immulogic Pharmaceutical Corporation Aus hausstaub isoliertes t-zellreaktives katzenprotein, und dessen verwendungen
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
ATE178940T1 (de) 1990-09-11 1999-04-15 Inst Child Health Research Klonierung und sequenzierung von dermatophagoiden-antigenen (hausstaubmilben)
WO1992007952A1 (en) 1990-10-30 1992-05-14 Immulogic Pharmaceutical Corporation Peptide binding assays with mhc antigens
WO1992011859A1 (en) 1991-01-08 1992-07-23 Immulogic Pharmaceutical Corporation Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite)
WO1993001213A1 (en) 1991-07-12 1993-01-21 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
IL103456A (en) * 1991-10-16 2006-06-11 Merck Patent Gmbh Isolated peptides having t-cell stimulating activity
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
HU220462B1 (hu) 1991-10-16 2002-02-28 Immulogic Pharmaceutical Corp. A Dermatophagoides nemzetség allergénjéből származó peptidek, ezeket tartalmazó gyógyszerkészítmények és eljárás házi poratka-érzékenység kimutatására
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
FI944697L (fi) 1992-04-09 1994-12-07 Immulogic Pharma Corp Ambrosia artemisiifolian pääallergeenien T-soluepitoopit
AU4796393A (en) 1992-07-31 1994-03-03 Immulogic Pharmaceutical Corporation Sensitive assay for antigens and antibodies and its use to identify rheumatoid arthritis antigen
AU5668194A (en) 1992-11-12 1994-06-08 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
DK0677105T3 (da) 1992-12-31 2006-07-10 Immulogic Pharma Corp Allergifremkaldende proteiner og peptider fra hundeskæl og anvendelser derfor
NZ263913A (en) 1993-03-12 1997-10-24 Immulogic Pharma Corp Lol pi protein allergen from ryegrass and related peptides coding sequences, vectors, protein production and use
AU674584B2 (en) * 1993-06-02 1997-01-02 Tvw Telethon Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
WO1995001597A2 (en) 1993-07-01 1995-01-12 British Telecomm System for generating instructions for speech application
FI960629L (fi) 1993-08-13 1996-04-12 Immulogic Pharma Corp Raiheinäsiitepöly allergeenin T-soluepitoopit
AU2238395A (en) 1994-04-01 1995-10-23 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
JPH09512014A (ja) 1994-04-14 1997-12-02 イミユロジク・フアーマシユーチカル・コーポレーシヨン ダニアレルギー治療用の医薬ペプチド組成物
WO1996007428A1 (en) * 1994-09-02 1996-03-14 Immulogic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
CZ122697A3 (en) 1994-10-25 1997-09-17 Immulogic Pharma Corp Preparations and methods of treating disseminated sclerosis
WO1996013589A1 (en) 1994-10-27 1996-05-09 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from ambrosia artemisiifolia
AU4695296A (en) 1995-01-06 1996-07-24 Immulogic Pharmaceutical Corporation Compositions and methods for treating rheumatoid arthritis
DE69738962D1 (de) 1996-03-10 2008-10-16 Meiji Dairies Corp Auf peptiden basierendes immunotherapeutisches mittel gegen allergien
US5804201A (en) 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5

Also Published As

Publication number Publication date
JP2000508627A (ja) 2000-07-11
GB0020260D0 (en) 2000-10-04
CA2247009A1 (en) 1997-09-25
GB2326642B (en) 2001-02-07
DE69733343D1 (de) 2005-06-30
EP1612555A1 (de) 2006-01-04
DK1612555T3 (da) 2009-02-09
EP0888541B1 (de) 2005-05-25
GB2349463B (en) 2001-01-10
GB2349463A (en) 2000-11-01
DE69739062D1 (de) 2008-12-04
EP0888541A1 (de) 1999-01-07
EP1612555B1 (de) 2008-10-22
US6737406B1 (en) 2004-05-18
WO1997035193A1 (en) 1997-09-25
AU730198C (en) 2002-03-14
AU2036597A (en) 1997-10-10
JP4340329B2 (ja) 2009-10-07
AU730198B2 (en) 2001-03-01
CA2247009C (en) 2009-08-04
GB9817461D0 (en) 1998-10-07
ATE296444T1 (de) 2005-06-15
GB0027373D0 (en) 2000-12-27
GB2326642A (en) 1998-12-30
GB2352518A (en) 2001-01-31
GB2352518B (en) 2001-04-04
ES2314515T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
HU9501276D0 (en) Stabile, liophylised composition containing proteins
DE69427370D1 (de) Neue integrinbindende peptide
DE4393381T1 (de) Peptide
ATE76309T1 (de) Dialyseloesung und ihre herstellung unter verwendung von peptiden auf der basis von glycin.
FI954559A0 (fi) YY-peptidin analogit ja niiden käytöt
ES2120964T3 (es) Peptidos osteogenicos.
DK6893D0 (da) Peptid
DE69333921D1 (de) "enhancer" sequenz zur modulation der expression in epithelialzellen
SE8803847A0 (sv) Neuromodulerande peptid
DE69739062D1 (de) Verwendung von kryptischen Peptiden zur Induktion von immunologischer Toleranz
FI961634A7 (fi) Antitromboottisia atsasykloalkyylialkanoyyli peptidejä ja pseudopeptid ejä
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
KR900011858A (ko) 혼성 아미노 수지 조성물
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
ZA946887B (en) Novel proteins/polypeptides and cotransfection plasmics and live recombinant carriers therefor
FI895456A7 (fi) Rekombinantti interleukiini 2-hybridiproteiineja
DE69534738D1 (de) Leukocyten-aktivierender Faktor
FI885301A7 (fi) Tekijä VIII:n puhdistuksessa käyttökelpoisia peptidejä
KR900011857A (ko) 혼성 아미노 수지 조성물
DE69613086D1 (de) Antigenen Peptide mit Glycinsubstitution
NO177858C (no) Peptid
KR900011855A (ko) 혼성 아미노 수지 조성물
IT9019021A0 (it) Composizioni a base di prolina,glicina e lisina per il trattamento della carenza di collagene
DE69635457D1 (de) Deprenyl induziertes protein
DE69030316D1 (de) Schrittweiser c-terminaler abbau von peptiden und proteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1612555

Country of ref document: EP